News - Page 115 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Health Canada Approves First Special Access Program Requests for Psilocybin

Health Canada Approves First Special Access Program Requests for Psilocybin

Post published:April 4, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022)

Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022)

Post published:April 1, 2022
Post category:Psychedelic Bulletin

Read more about the article Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

Post published:April 1, 2022
Post category:Press Release

Read more about the article Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

Post published:March 31, 2022
Post category:Press Release

Read more about the article Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Post published:March 31, 2022
Post category:Press Release

Read more about the article Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement

Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement

Post published:March 31, 2022
Post category:Press Release

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

Post published:March 30, 2022
Post category:Press Release

Read more about the article atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform

Post published:March 30, 2022
Post category:Press Release

Read more about the article Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia

Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia

Post published:March 30, 2022
Post category:Press Release

Read more about the article Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform

Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform

Post published:March 29, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.